COL17A1 and multiple sclerosis: that detected serum anti-BP180 NC16A IgG in only eight of 143 (5.6%) patients with multiple sclerosis and two of 140 (1.4%) neurologically healthy controls by ELISA, while none of these sera reacted with a glutathione-S-transferase NC16A fusion protein by immunoblotting (162).